Study Ties Pfizer Anti-Smoking Drug To Heart Problems

Law360, New York (July 5, 2011, 1:22 PM EDT) -- Pfizer Inc.'s smoking cessation drug Chantix has been linked to serious cardiovascular problems, such as congestive heart failure and stroke, according to an analysis published by a Canadian medical journal on Monday.

The analysis of 14 double-blind trials involving 8,216 participants published by the Canadian Medical Association Journal revealed a 72 percent increased risk of serious cardiovascular problems for those who took varenicline, the main ingredient in Chantix, compared to a placebo.

The analysis comes after the U.S. Food and Drug Administration reported in June that...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.